Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

Inclusion Criteria: * Any adult patient with active retinal vasculitis (involving arteries or veins) as a manifestation of non-infectious ocular inflammatory disease; fundus must be viewable with wide-field FA in the study eye * If both eyes are involved, both are eligible for inclusion in the study * Patients already on non-steroidal immunosuppressive therapy may continue on this during the study, but the dose must not be increased or decreased within 6 weeks of initiating the trial * Willing and able to sign the informed consent form Exclusion Criteria: * Patients under age 18 * Patients who are pregnant (must be ruled out in women of child-bearing age) * Active infectious ocular or systemic disease * Patients with active infectious ocular or extraocular disease * Patients with history of malignancy, except for dermatologic entities of basal or squamous cell carcinoma which have been completely excised or removed previously * Patients with systemic illness involving abnormalities of the hypothalamic-pituitary-adrenal axis; patients with primary adrenocortical insufficiency or adrenocortical hyperfunction * Patients with known hypersensitivity to Acthar * Patients on other non-steroidal systemic immunomodulatory medications with dose adjusted sooner than 6 weeks prior to study drug administration * Patients currently on or recently treated with (within 6 weeks) systemic corticosteroid * Patients with periocular or intraocular injections of medications administered to help…